
    
      Patients will be screened with the Ixabepilone DRP. If the tumor tissue has a DRP( Dose
      Response Prediction) score of >67% the patient can be included in the clinical study.
      Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle.
    
  